Avra Laboratories is first Company in the world
to develop a synthetic route for manufacturing of camptothecin derivatives. Avra manufacturing 7-Ethyl-10-hydroxycamptothecin (SN-38) in dedicated oncology facility which is approved by USFDA. we support USDMF and regulatory filing . offer 1 kg to 50 kgs level.
Advantages of SN-38:
Our product is made by total
synthesis as against other products available in the market.
Consistent quality in terms of purity and impurity profile.
Better yield of Irinotecan per gm of SN-38.
We will provide support both in terms of technical support and regulatory
requirements.
